Evidence map›Paper›PMID 30797042›Full record

ArticleContemporary clinical trials2019

A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.

Michael S Gordon, Frank J Vocci, Faye Taxman, Marc Fishman, Bikash Sharma, Thomas R Blue, Kevin E O'Grady

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael S GordonFriends Research Institute, Baltimore, MD, USA. Electronic address: mgordon@friendsresearch.org.
Frank J VocciFriends Research Institute, Baltimore, MD, USA.
Faye TaxmanDepartment of Criminology, Law & Society, George Mason University, Fairfax, VA, USA.
Marc FishmanMountain Manor Treatment Center, Baltimore, MD, USA.
Bikash SharmaMountain Manor Treatment Center, Baltimore, MD, USA.
Thomas R BlueDepartment of Criminology, Law & Society, George Mason University, Fairfax, VA, USA.
Kevin E O'GradyDepartment of Psychology, University of Maryland, College Park, MD, USA.

Funding

Buprenorphine for probationers and parolees: Bridging the gap into treatmentR01DA043476 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI GORDON, MICHAEL SCOTT · 2018 to 2023
$4.0M
Opiate Replacement Therapy at Release from IncarcerationR01DA018641 · NIDA · MIRIAM HOSPITAL · PI RICH, JOSIAH D · 2005 to 2009
$1.9M
NIDA NIH HHS R01 DA018641NIDA NIH HHS R01 DA043476
6 · The paper itself

Abstract

backgroundBuprenorphine can be effective in a variety of community substance use treatment settings outside of methadone programs, including outpatient programs and medical practices. In these settings, it has been found to be effective in reducing opioid use and retaining patients in treatment. Despite its effectiveness and safety, it is rarely provided to individuals with opioid use disorders in probation and parole settings.

methodsMale and female individuals under probation or parole supervision (N = 320) with histories of opioid use disorder will be enrolled in this randomized controlled trial. Participants will be randomized to one of two study arms: Buprenorphine Bridge Treatment (BBT): Participants will begin buprenorphine using the MedicaSafe dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to a community program; or Treatment as Usual (TAU): Participants will receive a referral to buprenorphine pharmacotherapy treatment in the community. Treatment outcomes will be: (a) illicit opioid oral saliva drug test results; and (b) treatment adherence (i. entered community based treatment; ii. number of days receiving opioid treatment).

resultsWe describe the background and rationale for the study, its aims, hypotheses, and study design.

conclusionsIf shown to increase compliance rates with conditions of probation and parole, buprenorphine treatment co-located at community supervision field offices could have a major impact on delivery of buprenorphine treatment to the criminal justice population. The public health impact of the proposed study would be widespread because this intervention could be implemented throughout areas of the US.

Indexed as

BuprenorphineCriminalsNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersAdolescentAdultAgedContinuity of Patient CareFemaleHumansMaleMedication AdherenceMiddle AgedRandomized Controlled Trials as TopicResearch DesignBuprenorphineNarcotic AntagonistsBuprenorphineCommunity supervisionOpioid use disorderParoleProbation

Identifiers

PMID30797042
PMCPMC6436986

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.